Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Implementation of flow cytometry in the diagnostic work-up of myelodysplastic syndromes in a multicenter approach: report from the Dutch Working Party on Flow Cytometry in MDS.
Westers TM, van der Velden VH, Alhan C, Bekkema R, Bijkerk A, Brooimans RA, Cali C, Dräger AM, de Haas V, Homburg C, de Jong A, Kuiper-Kramer PE, Leenders M, Lommerse I, te Marvelde JG, van der Molen-Sinke JK, Moshaver B, Mulder AB, Preijers FW, Schindhelm RK, van der Sluijs A, van Wering ER, Westra AH, van de Loosdrecht AA; Working Party on Flow Cytometry in MDS of Dutch Society of Cytometry (NVC). Westers TM, et al. Among authors: van wering er. Leuk Res. 2012 Apr;36(4):422-30. doi: 10.1016/j.leukres.2011.09.015. Epub 2011 Oct 6. Leuk Res. 2012. PMID: 21982641
Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol.
van der Velden VH, van der Sluijs-Geling A, Gibson BE, te Marvelde JG, Hoogeveen PG, Hop WC, Wheatley K, Bierings MB, Schuurhuis GJ, de Graaf SS, van Wering ER, van Dongen JJ. van der Velden VH, et al. Among authors: van wering er. Leukemia. 2010 Sep;24(9):1599-606. doi: 10.1038/leu.2010.153. Epub 2010 Jul 29. Leukemia. 2010. PMID: 20668473
Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR.
van der Velden VH, Willemse MJ, van der Schoot CE, Hählen K, van Wering ER, van Dongen JJ. van der Velden VH, et al. Among authors: van dongen jj, van der schoot ce, van wering er. Leukemia. 2002 May;16(5):928-36. doi: 10.1038/sj.leu.2402475. Leukemia. 2002. PMID: 11986956
Three-color flowcytometric analysis of mature and immature hematological malignancies. A guideline of the Dutch Foundation for Immunophenotyping of Hematological Malignancies (SIHON).
van Wering ER, van Lochem EG, Leenders M, van der Sluijs-Gelling AJ, Wind H, Gratama JW, Kraan J, Preijers FW. van Wering ER, et al. Among authors: van der sluijs gelling aj, van lochem eg. J Biol Regul Homeost Agents. 2004 Jul-Dec;18(3-4):313-26. J Biol Regul Homeost Agents. 2004. PMID: 15786698
Genome-wide expression analysis of paired diagnosis-relapse samples in ALL indicates involvement of pathways related to DNA replication, cell cycle and DNA repair, independent of immune phenotype.
Staal FJ, de Ridder D, Szczepanski T, Schonewille T, van der Linden EC, van Wering ER, van der Velden VH, van Dongen JJ. Staal FJ, et al. Among authors: van wering er. Leukemia. 2010 Mar;24(3):491-9. doi: 10.1038/leu.2009.286. Epub 2010 Jan 14. Leukemia. 2010. PMID: 20072147
Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
van der Velden VH, Jacobs DC, Wijkhuijs AJ, Comans-Bitter WM, Willemse MJ, Hählen K, Kamps WA, van Wering ER, van Dongen JJ. van der Velden VH, et al. Among authors: van dongen jj, van wering er. Leukemia. 2002 Aug;16(8):1432-6. doi: 10.1038/sj.leu.2402636. Leukemia. 2002. PMID: 12145681
Comparative analysis of T-cell receptor gene rearrangements at diagnosis and relapse of T-cell acute lymphoblastic leukemia (T-ALL) shows high stability of clonal markers for monitoring of minimal residual disease and reveals the occurrence of second T-ALL.
Szczepański T, van der Velden VH, Raff T, Jacobs DC, van Wering ER, Brüggemann M, Kneba M, van Dongen JJ. Szczepański T, et al. Among authors: van der velden vh, van dongen jj, van wering er. Leukemia. 2003 Nov;17(11):2149-56. doi: 10.1038/sj.leu.2403081. Leukemia. 2003. PMID: 14576730
Detection of minimal residual disease in acute leukemia.
van der Velden VH, Boeckx N, van Wering ER, van Dongen JJ. van der Velden VH, et al. Among authors: van dongen jj, van wering er. J Biol Regul Homeost Agents. 2004 Apr-Jun;18(2):146-54. J Biol Regul Homeost Agents. 2004. PMID: 15471219 Review.
Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation.
Lankester AC, Bierings MB, van Wering ER, Wijkhuijs AJ, de Weger RA, Wijnen JT, Vossen JM, Versluys B, Egeler RM, van Tol MJ, Putter H, Révész T, van Dongen JJ, van der Velden VH, Schilham MW. Lankester AC, et al. Among authors: van wering er. Leukemia. 2010 Aug;24(8):1462-9. doi: 10.1038/leu.2010.133. Epub 2010 Jun 10. Leukemia. 2010. PMID: 20535148
182 results